These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Goodman WK; Price LH; Delgado PL; Palumbo J; Krystal JH; Nagy LM; Rasmussen SA; Heninger GR; Charney DS Arch Gen Psychiatry; 1990 Jun; 47(6):577-85. PubMed ID: 2112374 [TBL] [Abstract][Full Text] [Related]
4. Serotonin dysfunction syndromes: a functional common denominator for classification of depression, anxiety, and obsessive-compulsive disorder. Benkert O; Wetzel H; Szegedi A Int Clin Psychopharmacol; 1993 Sep; 8 Suppl 1():3-14. PubMed ID: 8254151 [No Abstract] [Full Text] [Related]
5. A comparative examination of a role for serotonin in obsessive compulsive disorder, panic disorder, and anxiety. Murphy DL; Pigott TA J Clin Psychiatry; 1990 Apr; 51 Suppl():53-8; discussion 59-60. PubMed ID: 2139026 [TBL] [Abstract][Full Text] [Related]
7. L-5-hydroxytryptophan in depression and anxiety. van Praag HM; Kahn RS Schweiz Rundsch Med Prax; 1988 Aug; 77(34A):40-6. PubMed ID: 3055148 [No Abstract] [Full Text] [Related]
8. Serotonin and human myoclonus. Rationale for the use of serotonin receptor agonists and antagonists. Pranzatelli MR Arch Neurol; 1994 Jun; 51(6):605-17. PubMed ID: 7515228 [TBL] [Abstract][Full Text] [Related]
9. Alprazolam as treatment for a case of obsessive-compulsive disorder. Tesar GE; Jenike MA Am J Psychiatry; 1984 May; 141(5):689-90. PubMed ID: 6143507 [TBL] [Abstract][Full Text] [Related]
10. Symptom relapse in bulimia nervosa and obsessive compulsive disorder after treatment with serotonin antagonists. Hollander E; Mullen LS; Carrasco JL; DeCaria CM; Stein DJ J Clin Psychiatry; 1992 Jan; 53(1):28. PubMed ID: 1737737 [No Abstract] [Full Text] [Related]
11. Animal models in obsessive compulsive disorder. Olivier B Int Clin Psychopharmacol; 1992 Jun; 7 Suppl 1():27-9. PubMed ID: 1517553 [No Abstract] [Full Text] [Related]
12. Serotonin related functions in panic-anxiety: a critical overview. Coplan JD; Gorman JM; Klein DF Neuropsychopharmacology; 1992 May; 6(3):189-200. PubMed ID: 1534662 [TBL] [Abstract][Full Text] [Related]
14. New findings in obsessive-compulsive disorder. Kim SW; Dysken MW Minn Med; 1989 Feb; 72(2):91-3, 110. PubMed ID: 2651867 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of serotonin antagonists in depressive disorders. Wood MD; Thomas DR; Watson JM Expert Opin Investig Drugs; 2002 Apr; 11(4):457-67. PubMed ID: 11922855 [TBL] [Abstract][Full Text] [Related]
16. Serotonin-specific drugs for anxiety and depressive disorders. Charney DS; Krystal JH; Delgado PL; Heninger GR Annu Rev Med; 1990; 41():437-46. PubMed ID: 2139556 [TBL] [Abstract][Full Text] [Related]
17. Desensitization of terminal 5-HT autoreceptors by 5-HT reuptake blockers. de Montigny C; Blier P Arch Gen Psychiatry; 1991 May; 48(5):483-4. PubMed ID: 2021304 [No Abstract] [Full Text] [Related]
18. Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment. Zohar J; Insel TR; Zohar-Kadouch RC; Hill JL; Murphy DL Arch Gen Psychiatry; 1988 Feb; 45(2):167-72. PubMed ID: 3276283 [TBL] [Abstract][Full Text] [Related]
19. Serotonin syndrome from fluvoxamine and buspirone. Baetz M; Malcolm D Can J Psychiatry; 1995 Sep; 40(7):428-9. PubMed ID: 8548727 [No Abstract] [Full Text] [Related]